[
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Surpasses Market Returns: Some Facts Worth Knowing",
    "summary": "In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $178.41, denoting a +1.49% move from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=7034b1ce1d13c1889bbc401a66106621a9acbcb3c9280839a39cd3304fcc82f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757630704,
      "headline": "Johnson & Johnson (JNJ) Surpasses Market Returns: Some Facts Worth Knowing",
      "id": 136711256,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $178.41, denoting a +1.49% move from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=7034b1ce1d13c1889bbc401a66106621a9acbcb3c9280839a39cd3304fcc82f4"
    }
  },
  {
    "ts": null,
    "headline": "Prescription Drug Ads Face Big Changes. These Stocks Could Get Hurt the Most.",
    "summary": "Big changes could be coming to pharmaceutical advertising on TV, potentially causing problems for the broadcasters and networks that get paid to host those commercials.  TV watchers have become all too familiar with seeing prescription drug ads while watching their favorite programs.  Hearing personal stories about how  Novo Nordisk’s  Wegovy led to weight loss or that “healing is possible” with  Johnson & Johnson’s  Tremfya has become routine for viewers.",
    "url": "https://finnhub.io/api/news?id=ef031a64d1e0048d78b962fb09dfc743fa82b51b16d70e2c3d958543cd04d7e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757626800,
      "headline": "Prescription Drug Ads Face Big Changes. These Stocks Could Get Hurt the Most.",
      "id": 136703824,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Big changes could be coming to pharmaceutical advertising on TV, potentially causing problems for the broadcasters and networks that get paid to host those commercials.  TV watchers have become all too familiar with seeing prescription drug ads while watching their favorite programs.  Hearing personal stories about how  Novo Nordisk’s  Wegovy led to weight loss or that “healing is possible” with  Johnson & Johnson’s  Tremfya has become routine for viewers.",
      "url": "https://finnhub.io/api/news?id=ef031a64d1e0048d78b962fb09dfc743fa82b51b16d70e2c3d958543cd04d7e3"
    }
  },
  {
    "ts": null,
    "headline": "Warren Buffett wouldn’t worry about cash if he retired with just $1M — here’s why and how to copy his strategy",
    "summary": "Here's how you could copy the Oracle of Omaha in today's market.",
    "url": "https://finnhub.io/api/news?id=095d10f7cb6df7f5f226156f606f2be2d05e5929b36881079bec4fc69345824f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757615400,
      "headline": "Warren Buffett wouldn’t worry about cash if he retired with just $1M — here’s why and how to copy his strategy",
      "id": 136703799,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Here's how you could copy the Oracle of Omaha in today's market.",
      "url": "https://finnhub.io/api/news?id=095d10f7cb6df7f5f226156f606f2be2d05e5929b36881079bec4fc69345824f"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=770fd8036a3d40edd60e8eedb6b4ef88b4dbde8ba4b6f690c214cce3f9d75e09",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757599205,
      "headline": "Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know",
      "id": 136703826,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=770fd8036a3d40edd60e8eedb6b4ef88b4dbde8ba4b6f690c214cce3f9d75e09"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson seeks first European Medicines Agency approval for icotrokinra aiming to transform the plaque psoriasis treatment paradigm",
    "summary": "Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor.1 Filing based on four Phase 3 studies that met all primary and co-primary endpoints. This unprecedented data package includes head-to-head superiority comparisons versus deucravacitinib, adolescent data and evaluation of difficult to treat skin sites.2,3,4,5,6 Submission underscores that icotrokinra has the potential to offer moderate-to-severe plaque psoriasis patients the combinati",
    "url": "https://finnhub.io/api/news?id=bbc6db312b4612ae9058b028086613f2d7976c8bc554ffb2c71022261cf371e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757595360,
      "headline": "Johnson & Johnson seeks first European Medicines Agency approval for icotrokinra aiming to transform the plaque psoriasis treatment paradigm",
      "id": 136703827,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor.1 Filing based on four Phase 3 studies that met all primary and co-primary endpoints. This unprecedented data package includes head-to-head superiority comparisons versus deucravacitinib, adolescent data and evaluation of difficult to treat skin sites.2,3,4,5,6 Submission underscores that icotrokinra has the potential to offer moderate-to-severe plaque psoriasis patients the combinati",
      "url": "https://finnhub.io/api/news?id=bbc6db312b4612ae9058b028086613f2d7976c8bc554ffb2c71022261cf371e2"
    }
  },
  {
    "ts": null,
    "headline": "Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer",
    "summary": "Big Pharma faces tariff risks, patent cliffs, and regulatory pressure, but innovation and strong pipelines keep Eli Lilly, J&J, Novartis, Pfizer, and Bayer in focus.",
    "url": "https://finnhub.io/api/news?id=580827e731c758772aec40d1b08f43923e451206711d0a8fdb6e5d1f20f39222",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757582700,
      "headline": "Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer",
      "id": 136703787,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Big Pharma faces tariff risks, patent cliffs, and regulatory pressure, but innovation and strong pipelines keep Eli Lilly, J&J, Novartis, Pfizer, and Bayer in focus.",
      "url": "https://finnhub.io/api/news?id=580827e731c758772aec40d1b08f43923e451206711d0a8fdb6e5d1f20f39222"
    }
  }
]